Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial
17 December 2020
Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial Topline results on safety and dosing from Phase Ib portion of trial expected during Q3 2021 Phase II portion of trial can initiate following selection of dose regimen from Phase Ib trial
Immunicum AB (publ; IMMU.ST) announced today the completion of patient recruitment for the Phase Ib portion of the ongoing ILIAD (ILIxadencel in combination with checkpoint inhibitors in ADvanced cancer patients) trial. The primary objective of the Phase Ib study is to evaluate the safety and tolerability as well as define the dose regimen for Immunicum s lead cell-based candidate, ilixadencel, in combination with the checkpoint inhibitor (CPI), Keytruda (pembrolizumab), in a total of 21 patients.